摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(E)-3-{1'-benzyl-4-methyloxyimino-spiro[chromane-2,4'-piperidine]-6-yl}-N-hydroxy-acrylamide | 1192127-01-7

中文名称
——
中文别名
——
英文名称
(E)-3-{1'-benzyl-4-methyloxyimino-spiro[chromane-2,4'-piperidine]-6-yl}-N-hydroxy-acrylamide
英文别名
(E)-3-(1'-benzyl-4-methoxyiminospiro[3H-chromene-2,4'-piperidine]-6-yl)-N-hydroxyprop-2-enamide
(E)-3-{1'-benzyl-4-methyloxyimino-spiro[chromane-2,4'-piperidine]-6-yl}-N-hydroxy-acrylamide化学式
CAS
1192127-01-7
化学式
C24H27N3O4
mdl
——
分子量
421.496
InChiKey
AVSULUPTKRSAGG-UBDSCFFVSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.1
  • 重原子数:
    31
  • 可旋转键数:
    5
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    83.4
  • 氢给体数:
    2
  • 氢受体数:
    6

反应信息

  • 作为产物:
    描述:
    (E)-N-hydroxy-3-{1'-benzyl-4-oxospiro[chromane-2,4'-piperidine]-6-yl}acrylamide hydrochloride甲氧基胺盐酸盐吡啶 作用下, 以 乙醇 为溶剂, 反应 2.0h, 以94%的产率得到(E)-3-{1'-benzyl-4-methyloxyimino-spiro[chromane-2,4'-piperidine]-6-yl}-N-hydroxy-acrylamide
    参考文献:
    名称:
    Spirocyclic derivatives as histone deacetylase inhibitors
    摘要:
    这项发明涉及新的组蛋白去乙酰化酶抑制剂,其一般公式为(I),其中:虚线是可选的附加键;n为零或1至4之间的整数;R1为氢;C1-C6烷基,可选地被芳基或杂环烷基取代;(CO)R3;(SO2)R4;芳基;或杂环烷基;R2为C1-C6烷基,可选地被芳基或杂环烷基取代;芳基;杂环烷基;或(CO)R5;X为CH2,氧或NR6;Y为键,CHR7或NR8;Z为氧,CR9R10或C=R11;而R3、R4、R5、R6、R3、R8、R9、R10和R11如规范中进一步定义;以及其药用可接受的盐。
    公开号:
    EP2110377A1
点击查看最新优质反应信息

文献信息

  • SPIROCYCLIC DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS
    申请人:Varasi Mario
    公开号:US20140080823A1
    公开(公告)日:2014-03-20
    This invention is related to new histone deacetylase inhibitors according to the general formula (I) wherein: the dotted line is an optional additional bond; n is zero or an integer from 1 to 4; R 1 is hydrogen; C 1 -C 6 alkyl, optionally substituted by cycloalkyl, aryl or by heteroaryl; (CO)R 3 ; (SO 2 )R 4 ; cycloalkyl; aryl; or heteroaryl; R 2 is C 1 -C 6 alkyl, optionally substituted by aryl or by heteroaryl; aryl; heteroaryl; or (CO)R 5 ; X is CH 2 , oxygen or NR 6 ; Y is a bond, CHR 7 or NR 8 ; Z is oxygen, CR 9 R 10 or C═R 11 ; and R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 and R 11 are as further defined in the specification; and pharmaceutical acceptable salts thereof.
    本发明涉及新的组蛋白去乙酰化酶抑制剂,其通式为(I),其中:虚线是可选的额外键;n为零或1至4的整数;R1为氢;C1-C6烷基,可选地被环烷基、芳基或杂芳基取代;(CO)R3;(SO2)R4;环烷基;芳基;或杂芳基;R2为C1-C6烷基,可选地被芳基或杂芳基取代;芳基;杂芳基;或(CO)R5;X为CH2、氧或NR6;Y为键、CHR7或NR8;Z为氧、CR9R10或C═R11;而R3、R4、R5、R6、R7、R8、R9、R10和R11如规范中所进一步定义的;以及其药学上可接受的盐。
  • Spirocyclic derivatives as histone deacetylase inhibitors
    申请人:DAC S.r.l.
    公开号:EP2110377A1
    公开(公告)日:2009-10-21
    This invention is related to new histone deacetylase inhibitors according to the general formula (I) wherein: the dotted line is an optional additional bond; n is zero or an integer from 1 to 4; R1 is hydrogen; C1-C6 alkyl, optionally substituted by aryl or by heteroaryl; (CO)R3; (SO2)R4; aryl; or heteroaryl; R2 is C1-C6 alkyl, optionally substituted by aryl or by heteroaryl; aryl; heteroaryl; or (CO)R5; X is CH2, oxygen or NR6; Y is a bond, CHR7 or NR8; Z is oxygen, CR9R10 or C=R11; and R3, R4, R5, R6, R3 R8, R9, R10 and R11 are as further defined in the specification; and pharmaceutical acceptable salts thereof.
    这项发明涉及新的组蛋白去乙酰化酶抑制剂,其一般公式为(I),其中:虚线是可选的附加键;n为零或1至4之间的整数;R1为氢;C1-C6烷基,可选地被芳基或杂环烷基取代;(CO)R3;(SO2)R4;芳基;或杂环烷基;R2为C1-C6烷基,可选地被芳基或杂环烷基取代;芳基;杂环烷基;或(CO)R5;X为CH2,氧或NR6;Y为键,CHR7或NR8;Z为氧,CR9R10或C=R11;而R3、R4、R5、R6、R3、R8、R9、R10和R11如规范中进一步定义;以及其药用可接受的盐。
查看更多